Author Correction: PAK Signalling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas

Nature - United Kingdom
doi 10.1038/s41586-018-0814-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

PAK Signaling Promotes Acquired Resistance to BRAF and MEK Inhibitors

Cancer Discovery
Oncology
2017English

Correction: ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

Cancer Discovery
Oncology
2019English

Acquired Resistance to BRAF Inhibition in BRAFV600E Mutant Gliomas

Oncotarget
Oncology
2016English

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Cancer Research
Cancer ResearchOncology
2016English

mTORC1/autophagy-regulated MerTK in Mutant BRAFV600 Melanoma With Acquired Resistance to BRAF Inhibition

Oncotarget
Oncology
2017English

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2012English

A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-mutant Melanoma

Cancer Research
Cancer ResearchOncology
2020English

LB993 Focal Adhesions Mediate Rac1 P29S -Dependent Drug Resistance to MAPK Inhibitors in Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2017English

Inhibitors of Pan-Pi3k Signaling Synergize With BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Frontiers in Oncology
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy